This retrospective study assessed the clinical relevance of methylation profiling for meningioma risk stratification in 106 patients. Results indicated that methylation profiling, performed using the MethylationEPIC v1.0 chip, was a significantly superior predictor of tumor progression (r = -0.4, p < 0.001) compared to WHO 2021 grading. Although methylation profiling demonstrated enhanced predictive accuracy, particularly for identifying malignant meningiomas, its immediate clinical utility is constrained by a high rate of unclassified tumors (29%) and a delayed turnaround time for results (median 23 days), which is incompatible with prompt postoperative decision-making. The authors conclude that methylation profiling serves as a valuable complementary tool but cannot currently replace established histopathological assessment.
This study investigates epigenomic variations as drivers of clinical heterogeneity and progression in meningiomas. Using global DNA methylation profiling on large cohorts, researchers identified a hypermethylation signature correlated with clinical outcomes, providing more accurate prognostication. Longitudinal analysis revealed convergent contributions but differing plasticity of copy number variations and DNA hypermethylation. Furthermore, the study uncovered a tumor suppressive role for clustered protocadherins, which restrict β-catenin nuclear localization, a factor associated with meningioma progression.
This study investigated pan-TRK expression and NTRK gene aberrations in meningiomas. The findings indicate that pan-TRK expression is common in these tumors, especially in high-grade cases and those with high proliferative activity. While pan-TRK immunohistochemistry may assist in differentiating meningiomas from other central nervous system tumors, NTRK gene aberrations are rare. Therefore, molecular confirmation is crucial to identify patients who could benefit from TRK-targeted therapies.